http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20040764-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 |
| filingDate | 2003-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75cc35ed92bb3647576b5086a76be295 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd980ab0b758627986379937b983aeae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b75d8c1a3b7ac0847b8924a28fcc4ede |
| publicationDate | 2004-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20040764-A1 |
| titleOfInvention | INDAZOLE DERIVATIVES AS ANTAGONISTS OF CORTICOTROPIN RELEASE FACTOR (CRF) |
| abstract | REFERS TO INDAZOLE DERIVATIVES OF FORMULA IO II, WHERE R2 IS H, ALKYL (C1-C6), CYCLOALKYL (C3-C6), (CYCLOALKYL (C3-C6) -ALKYL (C1-C3), (ALKYL (C1 -C6)) CARBONYL, ALKYLSULPHONYL (C1-C6), ARYL OR ARYLALKYL WHICH ARE EVENTUALLY REPLACED BY ALKYL (C1-C6), HALOALKYL, ALCOXY (C1-C6) AND HALOGEN; EVENTUALLY IS ARYL OR HALOGENE ALKYL, EVENTUALLY SUBSTITUTED BY ALKYL (C1-C6), ALCOXY (C1-C6), ALKYLTIO (C1-C6), ALKYLSULFONILO (C1-C6), AMONG OTHERS; R1 IN THE CASE OF FORMULA I, IS -NRaRb, -CRcRdRe, CO2Ra or C ( O) NRaRb; IN THE CASE OF FORMULA II IT IS NRaRb, CrcRdRe, CO2Ra; OR IN THE CASE OF FORMULAS I OR II IT IS H, CYCLOALKENYL, ARYL OR HETEROARYL, WHICH ARE EVENTUALLY REPLACED BY ALKYL, (C1-C6) C6), ALKYLTIO (C1-C6), ALKYLSULFONYL (C1-C6), HALOGEN, AMONG OTHERS; Ra AND Rb ARE H, ALKYL (C1-C9), HYDROXYALKYL, (C1-C6 ALCOXY) -ALKYL, AMONG OTHERS; OR TOGETHER WITH N, THEY FORM A HETEROCYCLYL OR HETEROARYL RING.THE PREFERRED COMPOUNDS ARE: 7- (2,4-DICLO HYDROCHLORIDE RO-PHENYL) -2-METHYL-3- (1-PROPYL-BUT-1-ENYL) -2H-INDAZOLE, 2-METHYL-3- (1-PROPYL-BUT-1-ENYL) -7- ( 2,4,6-TRIMETHYL-PHENYL) -2H-INDAZOLE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE ANTAGONISTS OF RECEPTORS OF THE CRF FACTOR AND MAY BE USED FOR THE TREATMENT OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES SUCH AS THOSE RELATED TO STRESS, ANIMAL DISORDERS, EATING DISORDERS, ANXIETY, GASTROINTESTONE, DYSFUNCTION |
| priorityDate | 2002-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 40.